Oncopeptides to present updated data from the two ongoing trials ANCHOR and HORIZON in patients with RRMM at ASH in December 2018. The abstract data cut for ANCHOR was July 18th and for HORIZON, May 10th. Further data supporting melflufen’s activity has been generated since the abstract data cut and will be presented at ASH.
Upcoming presentations at ASH
The ANCHOR data will be presented as a poster on Saturday December 1st, at 6.15pm PST.
The HORIZON data will be presented as an oral presentation by Professor Paul G. Richardson, in the session “Antibodies and Targeted Therapies” on Monday December 3rd at 8.15am PST.
Paul G. Richardson, MD, is Professor of Medicine at Harvard Medical School and Clinical Program Leader, Director of Clinical Research at the Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute in Boston, Massachusetts, USA
The data to be presented at ASH will be based on data cuts during November (ANCHOR) and October (HORIZON) when more patients have been treated for evaluation than what is available in the abstracts.
ANCHOR abstract number #1967
HORIZON abstract number #600